Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma

NCT04354961 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
13
Enrollment
OTHER_GOV
Sponsor class

Conditions

Interventions

Sponsor

Fujian Cancer Hospital

Collaborators